Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Denifanstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sagimet Biosciences Presents At Fueling MASH: Symposium
    Sagimet Biosciences Presents At Fueling MASH: Symposium

    06 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/06/3268332/0/en/Sagimet-Biosciences-Announces-Poster-and-Oral-Presentations-at-the-Fueling-MASH-Metabolic-Drivers-and-Inflammatory-Crosstalk-Keystone-Symposium-and-Inducement-Grant-Under-Nasdaq-Li.html

    GLOBENEWSWIRE
    06 Apr 2026
    Share Share
    Sagimet Announces Positive 52-Wk Denifanstat Data in Severe MASH
    Sagimet Announces Positive 52-Wk Denifanstat Data in Severe MASH

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230125/0/en/Sagimet-Announces-Positive-52-Week-Data-from-License-Partner-Ascletis-Open-Label-Phase-3-Clinical-Trial-Evaluating-the-Long-Term-Safety-of-ASC40-Denifanstat-Tablets-in-Patients-wit.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Ascletis Reports Positive Phase III Results For Denifanstat
    Ascletis Reports Positive Phase III Results For Denifanstat

    29 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-its-phase-iii-open-label-study-of-denifanstat-asc40-a-first-in-class-once-daily-oral-fasn-inhibitor-for-acne-302673868.html

    PR NEWSWIRE
    29 Jan 2026
    Share Share
    Sagimet Biosciences Presents Poster At MASH-TAG 2026 Conference
    Sagimet Biosciences Presents Poster At MASH-TAG 2026 Conference

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215214/0/en/Sagimet-Biosciences-Announces-Poster-Presentation-at-the-10th-Annual-MASH-TAG-2026-Conference.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    TAPI and Sagimet Biosciences Announce Global License Agreement
    TAPI and Sagimet Biosciences Announce Global License Agreement

    19 Dec 2025

    // PRESS RELEASE

    https://tapi.com/knowledge-center/tapi-and-sagimet-biosciences-announce-global-license-agreement-for-innovative-forms-of-resmetirom-api-for-sagimets-fixed-dose-combination-program/

    PRESS RELEASE
    19 Dec 2025
    Share Share
    Sagimet Biosciences Reports Positive Phase 1 Results in PK Trial
    Sagimet Biosciences Reports Positive Phase 1 Results in PK Trial

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207571/0/en/Sagimet-Biosciences-Announces-Positive-Results-from-the-Phase-1-PK-Clinical-Trial-of-Denifanstat-and-Resmetirom-Combination.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.